SCHEMBL19782618

SCHEMBL19782618

COc1cc(F)c2nc(Br)sc2c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F2RL3 Q96RI0 2/20 0.44
MEN1 O00255 5/20 0.39
KMT2A Q03164 5/20 0.39
ALDH1A1 P00352 4/20 0.39
MAPT P10636 4/20 0.39
RAB9A P51151 3/20 0.39
PKM P14618 2/20 0.39
TDP1 Q9NUW8 2/20 0.39
HPGD P15428 3/20 0.38
LMNA P02545 2/20 0.38
GAA P10253 2/20 0.38
KDM4E B2RXH2 1/20 0.38
PSMD14 O00487 1/20 0.38
USP2 O75604 1/20 0.38
MMP13 P45452 1/20 0.38
HSD17B10 Q99714 1/20 0.38
ATG4B Q9Y4P1 1/20 0.38
APP P05067 1/20 0.37
TAAR1 Q96RJ0 1/20 0.37
CYP1A2 P05177 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19782519 0.81 ALDH1A1 (0.53) F2RL3ALDH1A1MAPTRAB9APKM
SCHEMBL30189983 0.81 ALDH1A1 (0.53) F2RL3ALDH1A1MAPTRAB9APKM
SCHEMBL19782939 0.81 F2RL3 (0.43) F2RL3MEN1KMT2AALDH1A1MAPT
SCHEMBL19782620 0.81 F2RL3 (0.45) F2RL3MEN1KMT2AALDH1A1MAPT
SCHEMBL19783358 0.79 F2RL3 (0.44) F2RL3ALDH1A1CYP1A2CYP3A4CYP2C19
SCHEMBL30189743 0.79 F2RL3 (0.44) F2RL3ALDH1A1CYP1A2CYP3A4CYP2C19
SCHEMBL19783572 0.76 RAB9A (0.62) MEN1KMT2AALDH1A1MAPTRAB9A
SCHEMBL17856111 0.76 ALDH1A1 (0.44) MEN1KMT2AALDH1A1MAPTRAB9A
SCHEMBL19783032 0.76 ALDH1A1 (0.39) MEN1KMT2AALDH1A1MAPTRAB9A
SCHEMBL19783403 0.76 L3MBTL1 (0.38) MEN1KMT2AALDH1A1MAPTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116041341-B Quinazoline PAR4 antagonist and medical application thereof 中国药科大学 2025-02-28 CN disclosed
CN-109689647-B Bicyclic heteroaryl substituted compounds 百时美施贵宝公司 2023-01-20 CN disclosed
US-20210163465-A1 BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS BRISTOL MYERS SQUIBB CO (US) 2021-06-03 US disclosed
US-20190292176-A1 BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS BISTOL MYERS SQUIBB COMPANY (US) 2019-09-26 US disclosed
WO-2018013774-A1 BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS BRISTOL-MYERS SQUIBB COMPANY (US) 2018-01-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190292176-A1 BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS F2, F2RL3, PF4 F2RL3 2/4885MEN1 1767/4885KMT2A 2420/4885
US-20210163465-A1 BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS F2, F2RL3, F12 F2RL3 2/4885MEN1 1492/4885KMT2A 2390/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.